Cloning ability of CAR-T cells in soft agar and tumorigenicity in vitro

doi:10.19803/j.1672-8629.2022.08.05

Abstract

Abstract: Objective To study whether CAR-T cells formed clones in soft agar, so as to evaluate its tumorigenicity in vitro and to provide safety data for future clinical use. Methods CAR-T cells were mixed with soft agar at different densities (1 000 ~ 5 000 per well) on 6-well culturing plates. Hela cells were set as positive control to count the clone formation rate. Results There were no cell colonies in the control group and the low (1 000 per well), medium (2 000 per well) and high dose groups (5 000 per well) within 14 days after culture. There were cell colonies in the positive control group at 14 days. Conclusion CAR-T cells do not have the ability to form soft agar clones in vitro . The tumorigenicity of CAR-T cells in vitro can be preliminarily investigated by using soft agar clone formation assay.

Key words: chimeric antigen receptor T (CAR-T) cells, tumorigenicity, soft agar cloning, nonclinical research, safety

CLC Number:

R979.1

HUANG Ying, WEN Hairuo, HOU Tiantian, HUO Yan, WANG Sanlong, GENG Xingchao. Cloning ability of CAR-T cells in soft agar and tumorigenicity in vitro[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 836-838.

References

[1] CHENG Z, LIU J, ZHONG JF, et al.Engineering CAR-T cells[J]. Biomarker Research, 2017, 5(1): 22.
[2] BAO BY, TANG GG, WANG XW, et al.Research progress on new anti-tumor immunotherapy drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(8): 719-724.
[3] HUANG Y, HOU TT, WEN HR, et al.Strategy and cases of preclinical safety evaluation of chimeric antigen receptor T cells products[J]. Chinese Journal of New Drugs(中国新药杂志), 2022, 31(8): 740-745.
[4] HUANG Y, HOU TT, HUO Y.Overview of the development and application of animal models in non-clinical studies of CAR-T cell therapy products[J]. Chinese Pharmaceutical Affairs(中国药事), 2018, 32(7): 886-892.
[5] LI YR, YANG C, LIU WD, et al.Seventy-three cases of suspected unexpected serious adverse reactions reports with chimeric antigen receptor T-cell therapy products[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(9): 600-606.
[6] Center for Drug Evaluation. Technical Guidelines for Research and Evaluation of Cell Therapy Products (Trial)[EB/OL].(2017-12-22)[2022-04-20]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=452c529b299638297210fe4a1294eb31.
[7] MENG SF, HUO Y, HOU TT, et al.Technical considerations on the quality control and nonclinical research for CAR-T cell therapy products[J]. Chinese Pharmaceutical Affairs(中国药事), 2018, 32(6): 829-852.
[8] LI YH, HUO Y, YU L, et al.Quality control and nonclinical research on CAR-T cell products: general principles and key issues[J]. Engineering, 2019, 5(1): 263-283.
[9] QU Z, LIN Z, HUO GT, et al.Risk assessment of tumorigenicity and oncogenicity of cell therapy product[J]. Chinese Journal of New Drugs(中国新药杂志), 2021, 30(19): 1819-1824.
[10] SATO Y, BANDO H, DI PIAZZA M, et al.Tumorigenicity assessment of cell therapy products: the need for global consensus and points to consider[J]. Cytotherapy, 2019, 21(11): 1095-1111.
[11] WEI Z, LYU S, WANG Y, et al.Biological characteristics of side population cells in a self-established human ovarian cancer cell line[J]. Oncol Lett, 2016, 12(1): 41-48.
[12] WEI ZT, YU XW, HE JX, et al.Characteristics of primary side population cervical cancer cells[J]. Oncol Lett, 2017, 14(3): 3536-3544.
[13] XIE T, MO L, LI L, et al.Identification of side population cells in human lung adenocarcinoma A549 cell line and elucidation of the underlying roles in lung cancer[J]. Oncol Lett, 2018, 15(4): 4900-4906.
[14] ZHANG KH, JIA CC, WU XL, et al.Growth Factors in a culture medium may enhance tumorigenic potency of human mesenchymal stem cells[J]. Chinese Medicinal Biotechnology(中国医药生物技术)2021, 16(6): 481-491.
[15] KUSAKAWA S, YASUDA S, KURODA T, et al.Ultra-sensitive detection of tumorigenic cellular impurities in human cell-processed therapeutic products by digital analysis of soft agar colony formation[J]. Sci Rep, 2015, 5: 17892.
[16] QIN SQ, KUSUMA GD, AL-SOWAYAN B, et al.Establishment and characterization of fetal and maternal mesenchymal stem/stromal cell lines from the human term placenta[J]. Placenta, 2016, 39: 134-146.
[17] MATHENI C, DSOUZA W.Xeno-free human Wharton's jelly mesenchymal stromal cells maintain their characteristic properties after long-term cryopreservation[J]. Cell J, 2021, 23(2): 145-153.
[18] ZHENG GF, XIE CF, XU SK, et al.Clony formation capability of human umbilical cord-derived mesenchymal stem cell in soft agar and its effects on tumor cell proliferation in vitro[J]. Chinese Journal of Cell and Stem Cell (Electronic Edition)(中华细胞与干细胞杂志(电子版)), 2016, 6(2): 97-104.
[19] QIN NS, GUO J, WANG X, et al.Tumor suppression effect and tumorigenicity of drugs evaluated by soft agar colony formation assay[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2017, 37(3): 444-450.